H.C. Wainwright raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps a Buy rating on the shares. The company presented the first comprehensive human and translational dataset for KT-621, its oral STAT6 degrader, “showing rapid, deep, and durable” STAT6 knock-down in both blood and skin at low daily doses, the analyst tells investors in a research note. The firm views the data as “convincing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements
- Kymera Therapeutics to present on KT-621 at EADV Congress
- Kymera Therapeutics initiated with an Overweight at Barclays
- Kymera Therapeutics initiated with an Outperform at RBC Capital
- Kymera Therapeutics Announces New Chief Legal Officer